BioNTech Presents Positive Preliminary Phase 1/2 Data for
BNT211 combines two innovative approaches in one regimen, an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a...
Source: globenewswire.com
Olide Tumore News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Olide Tumore. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.